Cypress Capital Management LLC grew its holdings in shares of Chemours Company (The) (NYSE:CC) by 0.5% in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 31,393 shares of the specialty chemicals company’s stock after buying an additional 155 shares during the period. Cypress Capital Management LLC’s holdings in Chemours Company (The) were worth $1,190,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also made changes to their positions in the company. Financial Architects Inc lifted its holdings in Chemours Company (The) by 1,230.3% during the 2nd quarter. Financial Architects Inc now owns 2,940 shares of the specialty chemicals company’s stock worth $111,000 after buying an additional 2,719 shares during the last quarter. Acrospire Investment Management LLC lifted its holdings in Chemours Company (The) by 3.4% during the 2nd quarter. Acrospire Investment Management LLC now owns 3,076 shares of the specialty chemicals company’s stock worth $117,000 after buying an additional 100 shares during the last quarter. Benjamin F. Edwards & Company Inc. lifted its holdings in Chemours Company (The) by 2,138.8% during the 2nd quarter. Benjamin F. Edwards & Company Inc. now owns 3,112 shares of the specialty chemicals company’s stock worth $118,000 after buying an additional 2,973 shares during the last quarter. Schroder Investment Management Group purchased a new stake in Chemours Company (The) during the 1st quarter worth about $156,000. Finally, Smithfield Trust Co. lifted its holdings in Chemours Company (The) by 521.4% during the 2nd quarter. Smithfield Trust Co. now owns 4,791 shares of the specialty chemicals company’s stock worth $182,000 after buying an additional 4,020 shares during the last quarter. 72.90% of the stock is owned by institutional investors.

In other news, insider E Bryan Snell sold 10,000 shares of the stock in a transaction dated Friday, August 11th. The shares were sold at an average price of $46.24, for a total transaction of $462,400.00. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, VP Amy Trojanowski sold 2,500 shares of the stock in a transaction dated Friday, August 11th. The stock was sold at an average price of $46.03, for a total transaction of $115,075.00. The disclosure for this sale can be found here. Insiders have sold 57,837 shares of company stock worth $2,885,523 in the last ninety days. Corporate insiders own 1.14% of the company’s stock.

A number of analysts have issued reports on CC shares. Zacks Investment Research raised Chemours Company (The) from a “hold” rating to a “strong-buy” rating and set a $61.00 price target for the company in a report on Tuesday, October 3rd. Citigroup Inc. raised Chemours Company (The) from a “neutral” rating to a “buy” rating and lifted their price target for the stock from $43.00 to $45.00 in a report on Wednesday, July 5th. Jefferies Group LLC reaffirmed a “buy” rating and set a $48.00 price target on shares of Chemours Company (The) in a report on Friday, June 16th. BidaskClub raised Chemours Company (The) from a “hold” rating to a “buy” rating in a report on Wednesday, July 12th. Finally, J P Morgan Chase & Co lifted their price target on Chemours Company (The) to $55.00 and gave the stock an “overweight” rating in a report on Friday, August 4th. One analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Chemours Company (The) has a consensus rating of “Buy” and an average price target of $52.75.

Chemours Company (NYSE CC) traded up 0.04% during mid-day trading on Monday, hitting $54.69. The stock had a trading volume of 488,367 shares. The company has a 50 day moving average price of $51.45 and a 200 day moving average price of $51.45. Chemours Company has a one year low of $14.41 and a one year high of $54.96. The stock has a market cap of $10.11 billion, a P/E ratio of 35.79 and a beta of 3.60.

Chemours Company (The) (NYSE:CC) last issued its quarterly earnings results on Wednesday, August 2nd. The specialty chemicals company reported $0.87 EPS for the quarter, topping the consensus estimate of $0.85 by $0.02. Chemours Company (The) had a net margin of 4.96% and a return on equity of 122.97%. The business had revenue of $1.59 billion for the quarter, compared to analysts’ expectations of $1.49 billion. During the same quarter last year, the company posted $0.27 earnings per share. The company’s quarterly revenue was up 14.8% compared to the same quarter last year. On average, equities analysts anticipate that Chemours Company will post $3.51 EPS for the current year.

The business also recently declared a quarterly dividend, which was paid on Friday, September 15th. Stockholders of record on Thursday, August 17th were given a dividend of $0.03 per share. The ex-dividend date was Tuesday, August 15th. This represents a $0.12 annualized dividend and a dividend yield of 0.22%. Chemours Company (The)’s payout ratio is 8.11%.

TRADEMARK VIOLATION WARNING: This report was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this report on another site, it was illegally stolen and republished in violation of United States and international copyright laws. The original version of this report can be read at https://www.thecerbatgem.com/2017/10/09/chemours-company-the-cc-holdings-increased-by-cypress-capital-management-llc.html.

Chemours Company (The) Company Profile

The Chemours Company is a provider of performance chemicals. The Company operates through three segments: Titanium Technologies, Fluoroproducts and Chemical Solutions. The Titanium Technologies segment is a producer of titanium dioxide (TiO2). The Fluoroproducts segment is a provider of fluoroproducts, including refrigerants and industrial fluoropolymer resins.

Want to see what other hedge funds are holding CC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Chemours Company (The) (NYSE:CC).

Institutional Ownership by Quarter for Chemours Company (The) (NYSE:CC)

Receive News & Stock Ratings for Chemours Company (The) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemours Company (The) and related stocks with our FREE daily email newsletter.